Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)Product type:GuidanceProgramme:HealthTech guidancePublished: 3 September 2020
GreenLight XPS for treating benign prostatic hyperplasia (HTG650)Product type:GuidanceProgramme:HealthTech guidancePublished: 29 November 2022
Lower urinary tract symptoms in men: management (CG97)Product type:GuidanceProgramme:Clinical guidelineLast updated: 3 June 2015Published: 23 May 2010
Mirabegron for treating symptoms of overactive bladder (TA290)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 June 2013
Optilume for treating recurrent bulbar urethral strictures (HTG649)Product type:GuidanceProgramme:HealthTech guidancePublished: 29 November 2022
Prostatitis (acute): antimicrobial prescribing (NG110)Product type:GuidanceProgramme:NICE guidelinePublished: 31 October 2018
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)Product type:GuidanceProgramme:HealthTech guidancePublished: 24 June 2020
Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal) (TA273)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2013
The PLASMA system for transurethral resection and haemostasis of the prostate (HTG563)Product type:GuidanceProgramme:HealthTech guidancePublished: 6 January 2021
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (HTG578)Product type:GuidanceProgramme:HealthTech guidancePublished: 4 May 2021
Vibegron for treating symptoms of overactive bladder syndrome (TA999)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 September 2024